Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of AR117649A1publicationCriticalpatent/AR117649A1/en
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Abstract
La presente proporciona anticuerpos que se unen a la proteína de Receptor de Activación Humano Expresado en células Mieloides 2 (TREM2) y la estabilizan, y métodos para usar estos anticuerpos.The present invention provides antibodies that bind and stabilize Myeloid Cell Expressed Human Activation Receptor 2 (TREM2) protein, and methods of using these antibodies.
Labeled antibody and / or fragment thereof comprising a monoclonal antibody or a fragment thereof, which specifically binds human tau; nucleic acid that encodes it; vector; cell; method of producing antibody; and use of the same to inhibit the aggregation of tau, and associated diseases (divisional application no. 202001003)